Immunodermatology News

Based on the pathogenesis of eosinophilic cellulitis, treatment targeting Janus kinase 1 and 2 should be developed to treat this disease, according to a study.

Clinicians should consider rubella virus as a potential contributor to granulomatous skin disease in both immunodeficient and immunocompetent patients, according to a study.

Nielsen BioSciences Inc. and Maruho Co. Ltd. have entered into a licensing agreement that grants Maruho an exclusive license to market CANDIN in Japan for the treatment of verruca vulgaris, according to a press release.

The mRNA-based COVID-19 vaccine does not significantly increase the risk of autoimmune or autoinflammatory diseases, according to data published in the Journal of the American Academy of Dermatology.

DESTIN, Fla. — Complicated disease pathogenesis and a lack of FDA-approved therapies makes sarcoidosis a significant clinical challenge, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.

NEW ORLEANS — Janus kinase inhibitors could be promising in the treatment of cutaneous sarcoidosis, which currently has no FDA-approved treatment options, according to a speaker here.

Details on pain recall may be necessary to supplement the numerical rating and VAS for pain assessment in clinical trials of hidradenitis suppurativa, according to a study.

WAILEA, Hawaii — Janus kinase inhibitors could be the future of alopecia areata treatment in children if research proves them to be safer than current warnings suggest, according to a presenter at the Maui Derm meeting.

About half of the patients with catastrophic antiphospholipid syndrome have cutaneous involvement, which can help predict outcomes in this condition, according to a study.

Rituximab is associated with higher protection against long-term cardiovascular and metabolic diseases, but similar in survival rate, compared with other adjuvant agents in the treatment of pemphigus, according to a study.